|
시장보고서
상품코드
2084636
DMARD(Disease-Modifying Antirheumatic Drug) 시장 : 약제 유형별, 투여 경로별, 적응증별, 유통 채널별, 지역별Disease-Modifying Antirheumatic Drug (DMARD) Market, By Drug Type, By Route of Administration, By Indication, By Distribution Channel, By Geography |
||||||
DMARD(Disease-Modifying Antirheumatic Drug) 시장은 2026년에 237억 2,000만 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 301억 8,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 3.5%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 237억 2,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 3.50% | 2033년 시장 규모 예측 : | 301억 8,000만 달러 |
DMARDs(Disease-modifying anti-rheumatic drugs)는 질병의 근본적인 원인을 치료하고 염증을 완화할 수 있습니다. 이 약들은 류마티스 관절염, 건선성 관절염, 전신성 홍반성 루푸스, 강직성 척추염 등의 자가면역 질환을 앓고 있는 환자에게 투여됩니다. 이 질환들은 보통 감염과 싸우는 면역 체계가 자신의 건강한 조직을 공격해 버리는 질환입니다. DMARD는 통증, 뻣뻣함, 부기 등의 증상을 개선할 수 있지만, 효과가 충분히 나타나기까지는 몇 주, 경우에 따라는 몇 달이 걸릴 수도 있습니다. DMARD에는 다양한 유형이 있으며, 그 작용 기전도 다소 다릅니다. 주요 3가지 유형로는 합성 DMARD(sDMARD), 표적형 합성 DMARD, 생물학적 DMARD(bDMARD) 등이 있습니다.
시장 역학
전 세계 질환 수정 항류마티스제(DMARD) 시장에서 활동하는 주요 기업은 신제품 출시 및 승인 확대에 주력하고 있으며, 이는 예측 기간 중 시장 성장을 촉진할 것으로 전망됩니다. 예를 들어 2018년 1월, 대형 제네릭 의약품 기업 중 하나인 헤테로(Hetero)사는 인도에서 네 번째 바이오시밀러인 ‘아달리무맙’을 ‘마브라’라는 브랜드명으로 출시했습니다. 'Mabura'는 인간 종양괴사인자(TNF)를 표적으로 하는 항염증성 생물제제입니다. 류마티스 관절염, 건선성 관절염, 강직성 척추염, 크론병, 궤양성 대장염 등 기타 자가면역 질환의 치료에 사용됩니다. 또한 2020년 9월, 미국의 다국적 제약·바이오기술 기업인 화이자(Pfizer)는 미국 식품의약국(FDA)이 활동성 다관절형 소아 특발성 관절염(pcJIA)을 앓고 있는 2세 이상의 소아 및 청소년을 위한 치료제로 'XELJANZ(토파시티닙)'를 승인했다고 발표했습니다. 정제와 내복액, 두 가지 제형이 승인되었으며, 투여량은 체중에 따라 결정됩니다. 이번 승인으로 XELJANZ는 미국에서 pcJIA 치료제로 승인된 최초이자 유일한 야누스 키나제(JAK) 억제제가 되었습니다.
본 조사의 주요 특징.
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하고 있는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음의 주요 지표(기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적, 전략)를 바탕으로 전 세계 질환 수정 항류마티스제(DMARD) 시장의 주요 기업 개요을 소개하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 이 '세계의 질환 수정 항류마티스제(DMARDs) 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 질환 수정 항류마티스제(DMARDs) 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 DMARD(Disease-Modifying Antirheumatic Drug) 시장 : 약제 유형별, 2021-2033년
제5장 세계의 DMARD(Disease-Modifying Antirheumatic Drug) 시장 : 투여 경로별, 2021-2033년
제6장 세계의 DMARD(Disease-Modifying Antirheumatic Drug) 시장 : 적응증별, 2021-2033년
제7장 세계의 DMARD(Disease-Modifying Antirheumatic Drug) 시장 : 유통 채널별, 2021-2033년
제8장 세계의 DMARD(Disease-Modifying Antirheumatic Drug) 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 섹션
KSA 26.07.14Disease-Modifying Antirheumatic Drug (DMARD) Market is estimated to be valued at USD 23.72 Bn in 2026 and is expected to reach USD 30.18 Bn by 2033, growing at a compound annual growth rate (CAGR) of 3.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 23.72 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.50% | 2033 Value Projection: | USD 30.18 Bn |
Disease-modifying anti-rheumatic drugs (DMARDs) can treat the underlying cause of condition and reduce inflammation. They are given to people with autoimmune conditions, such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis and others. These are conditions where the immune system, which normally fights infection, attacks the body's own healthy tissues. DMARDs can improve symptoms such as pain, stiffness and swelling, but they may take a few weeks or even months to fully take effect. There are different types of DMARDs, and they work in slightly different ways. The three main types are: synthetic (sDMARD), targeted synthetic DMARDs, biological DMARDs (bDMARD) and others
Market Dynamics
Key players operating in the global disease-modifying anti-rheumatic drugs (DMARDs) market are focusing on increasing product launches and product approvals which is expected to drive the market growth during the forecast period. For instance, in January 2018, Hetero, one of the leading generic pharmaceutical companies launched its fourth biosimilar drug 'Adalimumab' under the brand name 'Mabura' in India. Mabura is an anti-inflammatory biologic medication specific for human tumor necrosis factor (TNF). It is indicated for the treatment of rheumatoid arthritis and other auto-immune disorders such as psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. Moreover, in September 2020, Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation announced that the U.S. Food and Drug Administration (FDA) approved XELJANZ (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight. This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global disease-modifying anti-rheumatic drugs (DMARDs) market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
- Key companies covered as a part of this study include Sanofi., Pfizer, F. Hoffman-La Roche AG, Johnson & Johnson, AbbVie Inc., Eli Lilly & Company, Amgen Inc., Swedish Orphan Biovitrum AB, Bristol-Myers Squibb Company, UCB S.A., Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global disease-modifying anti-rheumatic drugs (DMARDs) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global disease-modifying anti-rheumatic drugs (DMARDs) market
Market Segmentation
- By Drug Type (Revenue, USD Bn, 2021-2033)
- Synthetic (sDMARD)
- Conventional synthetic (csDMARDs)
- Methotrexate
- Sulfasalazine
- Leflunomide
- Hydroxychloroquine
- Gold Salts
- Targeted synthetic DMARDs (tsDMARDs)
- Biological DMARDs (bDMARD)
- Original DMARDs (boDMARDs)
- Biosimilar DMARDs (bsDMARDs)
- Primary
- Secondary
- Tertiary
- Others
- By Route of Administration (Revenue, USD Bn, 2021-2033)
- Oral
- Parenteral
- Others
- By Indication (Revenue, USD Bn, 2021-2033)
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Systemic Lupus Erythematosus
- Others
- By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Region (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Pfizer
- Hoffman-La Roche AG
- Johnson & Johnson
- AbbVie Inc.
- Eli Lilly & Company
- Amgen Inc.
- Swedish Orphan Biovitrum AB
- Bristol-Myers Squibb Company
- UCB S.A.
- Gilead Sciences, Inc.
- Cumberland Pharmaceuticals Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Drug Type, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Synthetic (sDMARD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Conventional synthetic (csDMARDs)
- Methotrexate
- Sulfasalazine
- Leflunomide
- Hydroxychloroquine
- Gold Salts
- Targeted synthetic DMARDs (tsDMARDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Biological DMARDs (bDMARD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Original DMARDs (boDMARDs)
- Biosimilar DMARDs (bsDMARDs)
- Primary
- Secondary
- Tertiary
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
5. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Route of Administration, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
6. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Indication, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Ankylosing Spondylitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Psoriatic Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Systemic Lupus Erythematosus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
7. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Distribution Channel, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
8. Global Disease-Modifying Antirheumatic Drug (DMARD) Market, By Region, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Rout of Administration 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Sanofi
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- F. Hoffman-La Roche AG
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Eli Lilly & Company
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Swedish Orphan Biovitrum AB
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- UCB S.A.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cumberland Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Sanofi
- Analyst Views
10. Section
- References
- Research Methodology
- About Us
